Mira Pharmaceuticals Announces Promising Results from Ketamir-2 Study for PTSD Treatment
Mira Pharmaceuticals Inc. has announced positive results from a proof-of-concept validation study of its oral drug candidate, Ketamir-2, aimed at treating post-traumatic stress disorder (PTSD). The study, conducted on rats using the Single Prolonged Stress model, showed that Ketamir-2 restored normalized behavior in stressed animals. Animals were exposed to a predator stressor, which induced PTSD-like symptoms, and were then treated with Ketamir-2. The treatment was associated with a reversal of PTSD-like behaviors to levels observed in non-stressed animals. Ketamir-2 targets the NMDA receptor with low affinity and has demonstrated superior efficacy in preclinical studies compared to ketamine, pregabalin, and gabapentin. It is not considered a controlled substance by the U.S. Drug Enforcement Administration. The company is conducting a larger follow-on PTSD study and a Phase 1 clinical trial for neuropathic pain, where Ketamir-2 has shown a favorable safety profile.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mira Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-25-013459), on September 15, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.